Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BMS 986326

Next Previous
Search
Drug Profile

BMS 986326

Alternative Names: BMS-986326

Latest Information Update: 16 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Anti-inflammatories; Skin disorder therapies
  • Mechanism of Action Interleukin-2 receptor alpha subunit antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Atopic dermatitis; Autoimmune disorders; Immunological disorders

Most Recent Events

  • 16 May 2024 Phase I development for Immunological-disorders (In volunteers) is ongoing in Germany (IV) (NCT04736134)
  • 16 May 2024 Phase I development for Immunological-disorders (In volunteers) is ongoing in Germany (SC) (NCT04736134)
  • 21 Mar 2024 Phase-I clinical trials in Atopic dermatitis (In adults, In the elderly) in Spain, Poland, Germany, France, Czech Republic (unspecified route) (NCT06248814)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top